💓 Statin Dose-Response & Myopathy Risk Simulator

Baseline Elevated LDL Cholesterol

High LDL drives atherosclerotic risk before treatment.

• 160-190: Typical baseline LDL (mg/dL, untreated)
• <70: Target LDL (high risk) (mg/dL, guideline goal)
• ~200 M: Global statin users (worldwide estimate)
• #1: ASCVD risk driver (modifiable lipid factor)

Why LDL matters

LDL particles seed arterial plaque over years of exposure.

Who gets treated

Risk calculators combine LDL, age, and comorbidities.

Before therapy

Baseline labs set the reference point for dosing.

Statin Initiation & HMG-CoA Reductase

A starting dose blocks cholesterol synthesis in the liver.

• HMG-CoA: Target enzyme (reductase, rate-limiting step)
• 10-20: Typical starting dose (mg equivalent)
• ~2 wk: Onset of effect (to steady-state LDL drop)
• ↑: LDL receptor upregulation (compensatory hepatic response)

Enzyme blockade

Statins competitively inhibit the mevalonate pathway.

Hepatic response

Liver upregulates LDL receptors to compensate.

Starting low

Low starting doses limit early side-effect exposure.

Dose-Response Curve — The Rule of Six

Each dose doubling adds roughly six more points of LDL drop.

• ~6%: Rule of six (extra LDL cut per doubling)
• ~30→48%: 10mg → 80mg reduction (diminishing returns)
• Logarithmic: Curve shape (not linear with dose)
• 3: Dose doublings shown (10→20→40→80 mg)

Logarithmic gains

Big early gains shrink with every further dose step.

Clinical implication

Doubling dose rarely doubles benefit.

Practical ceiling

High doses buy little extra LDL-lowering.

Myopathy Risk Rises Disproportionately

Muscle risk accelerates with dose, especially with interacting drugs.

• CYP3A4: Myopathy mechanism (metabolism competition)
• Rare: Rhabdomyolysis (but dose- and drug-linked)
• Fibrates,: High-risk interactors (azoles, some antibiotics)
• Steepening: Risk curve shape (not linear with dose)

CYP3A4 competition

Interacting drugs raise statin blood levels sharply.

Dose amplification

High dose plus interaction compounds risk fastest.

Warning signs

Muscle pain, weakness, and dark urine need review.

Finding the Optimal Dose Window

Best dosing maximizes LDL benefit while limiting muscle risk.

• 20-40: Optimal window (no interaction) (mg equivalent)
• 11-16: Window with strong interaction (mg equivalent, narrowed)
• Lowest: Guiding principle (effective dose strategy)
• Med list: Key clinical check (review before uptitration)

Balancing act

Optimal dose trades marginal LDL gain for real risk.

Interaction check

Co-prescribed drugs shrink the safe dosing window.

Shared decision

Dose choice weighs patient risk and preference.